Blood Cancer Clinical Trials
- View all
Myeloid Diseases
Name Locations MyeloMATCH: Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials RH Learn More MyeloMATCH MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FL T3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial RH Learn More MyeloMATCH MM1YA-CTG01: A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML): A Tier 1 MyeloMATCH Clinical Trial RH Learn More MyeloMATCH MM1YA-S01: A Randomized Phase II Study Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia (AML) as Determined by MyeloMATCH: A MyeloMATCH Clinical Trial RH Learn More Myeloma
Name Locations BMS CA204008: Prospective Research Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE) PTN Learn More EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) PTN, RH Learn More ECOG-ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation RH Learn More Lymphoma
Name Locations AbbVie M23-362: A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting RH Learn More
Brain and Spinal Cord Cancer Clinical Trials
- View all
Name Locations Alliance-A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma RH Learn More NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma RH Learn More NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma RH Learn More NRG-BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases RH Learn More
Breast Cancer Clinical Trials
- View all
Name Locations A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib PHX, PTN, RH Learn More A191901: The GET SET Study (Phase III, Randomized, Therapeutic Trial) PHX Learn More AstraZeneca AB/CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence RH Learn More CK-SAPBI: CyberKnife Stereotactic Accelerated Partial Breast Irradiation Registry PTN Learn More EA1181: (CompassHER2 pCR) Preoperative THP and postoperative HP in patients who achieve a pathologic complete response PHX Learn More Gilead Sciences, Inc./ASCENT-5: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer (TNBC) Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy RH Learn More NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) RH Learn More NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial RH Learn More NRG-CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node-Positive Breast Cancer RH Learn More S2010/ASPEN: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer PHX, RH Learn More
Colon and Digestive Tract Cancer Clinical Trials
- View all
Anal
Name Locations ECOG/ACRIN-EA2182: A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE) RH Learn More Colon/Rectal
Name Locations 16-002/NSABP C-14: CORRECT-MRD II: Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease RH Learn More A022104: The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer RH Learn More NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) RH Learn More NRG-GI004: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer RH Learn More S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and IrinotecN (cetiri) IN Advanced/Medtastatic Colorectal Cancer (mCRC) with HER-2-Amplification Pottstown Hospital Active Clinical Trials PTN Learn More S2107: Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer RH Learn More Esophageal and Gastric
A022102: A Randomized Phase III Trial of mFOLFIRINOX +/– Nivolumab vs. FOLFOX +/– Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma RH Learn More EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma PTN, RH Learn More ECOG/ACRIN-EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma RH Learn More Pancreatic
Alliance-A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer RH Learn More TJU-08D.213: Jefferson Pancreas Tumor Registry (JPTR) RH Learn More
Gynecologic Cancer Clinical Trials
- View all
Name Locations S1714: Neuropathy Trial (Observational Study) PHX Learn More
Head and Neck Cancer Clinical Trials
- View all
Name Locations EA3132: Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing PTN Learn More ECOG/ACRIN-EA3132: Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing RH Learn More ECOG-ACRIN EA3161: A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC RH Learn More
Lung Cancer Clinical Trials
- View all
Small Cell
Name Locations A151216: Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist) PTN, RH Learn More SWOG S1827/MAVERICK: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer RH Learn More Non-Small Cell
Name Locations A081801: Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small Cell Lung Cancer (NSCLC): ALCHEMIST Chemo-IO PTN, RH Learn More E4512: A Phase III Double-Blind Trial of Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein PTN Learn More EA5163: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis PTN Learn More EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC PTN Learn More EA5221: A Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study RH Learn More LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study) PTN Learn More NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer RH Learn More S1714: Neuropathy Trial (Observational Study) PHX Learn More S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (LUNG MAP Sub Study) Learn More Lung Cancer Screening
Name Locations Lighthouse: Peripheral blood samples will be collected from individuals who have a planned lung cancer screening by LDCT and meet the protocol eligibility criteria. The blood samples and subject data will be used in Roche-sponsored studies for the development of cancer screening and detection products RH Learn More
Pre-Cancer Screening Clinical Trials
- View all
Name Locations Lighthouse - Roche Cancer Screening Collection Study: Pre-screening for lung cancer RH Learn More
Prostate, Kidney, and Urologic Cancer Clinical Trials
- View all
Prostate
Name Locations EA8184: A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers RH Learn More NRG-GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy RH Learn More NRG-GU009: Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT) RH Learn More NRG-GU010: Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) RH Learn More NRG-GU013: The Phase III ‘High Five Trial’ Five Fraction Radiation for High-Risk Prostate Cancer RH Learn More TJU-17C.072: Prostate cancer outcomes: An international registry to improve outcomes in men with advanced prostate cancer (IRONMAN) RH Learn More Renal (Kidney)
Name Locations NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) RH Learn More Urothelial
Name Locations EA8192: A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy RH Learn More
Skin Cancer Clinical Trials
- View all
Name Locations ECOG/ACRIN-EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma RH Learn More
Research Locations
McGlinn Cancer Institute at Reading Hospital
Located on T-Ground floor of Reading Hospital, McGlinn Cancer Institute is the Tower Health network’s renowned clinical and research facility with satellite offices at Phoenixville and Pottstown Hospitals. Nationally recognized for its leading-edge treatment options, McGlinn Cancer Institute provides patients with the highest standard of cancer care. The hospitals are accredited by the Commission on Cancer (CoC) of the American College of Surgeons (ACS), National Accreditation Program for Breast Centers (NAPBC) and the American College of Radiation Oncology (ACR), which requires providers to meet the most stringent clinical guidelines. McGlinn Cancer Institute offers genetic counseling, the most advanced radiation therapies, multidisciplinary teams, image guided radiation therapy, advanced chemotherapy and immunotherapy, interventional radiology, minimally invasive and complex surgeries, plus support services and rehabilitation programs.
The Cancer Research Office (CRO) conducts Phase II-IV NCI funded cooperative group trials, is a Main Voting Member of NRG and is an Affiliate Member of ECOG-ACRIN cooperative group and is a part of NCI’s National Clinical Trials Network. Additionally, the CRO conducts Pharmaceutical sponsored research, as well as intra-institutional studies with institutions such as Thomas Jefferson, Penn, SKCC, Indiana University, and Johns Hopkins with the JHCRN. Known for its cutting-edge clinical trials afforded to their community members, the CRO has been nationally recognized for their excellent performance and meticulous management in conducting oncology clinical trials. Supporting trials from a variety of disciplines affords the CRO to maintain a robust and diverse clinical trial portfolio with more than 130 active trials being conducted. For more information, please contact the CRO at 484-628-8193.
McGlinn Cancer Institute at Phoenixville Hospital
Located at 140 Nutt Road in Phoenixville, PA, Phoenixville Hospital is a 144-bed facility that provides comprehensive medical services through emergency room visits, inpatient admissions, outpatient procedures and community outreach programs. It is home to an award-winning cardiovascular program, and is a fully accredited McGlinn Cancer Center satellite location. Phoenixville also has an NAPBC-accredited breast health center, CoC of the ACS accreditation in addition to having an acute inpatient rehabilitation center, and a large robotic surgery program.
Phoenixville Hospital is accredited by The Joint Commission and has been recognized for its quality outcomes and clinical expertise across services lines that include advanced joint replacement surgery, advanced heart failure care, and the designation as a Primary Stroke Center.
The Phoenixville Cancer Research Office (PHX) conducts Phase II-IV NCI funded cooperative group trials, and is an Affiliate Member of ECOG-ACRIN cooperative group which is a part of NCI’s National Clinical Trials Network. Additionally, PHX conducts NRG and other cooperative group trials sponsored by the NCI. Intra-institutional studies with the likes of Thomas Jefferson and the University of Rochester are conducted in addition to grant-funded research. Known for its cutting edge clinical trials afforded to their community members, the comprehensive clinical trial portfolio that PHX maintains continues to grow to address the needs of the diverse community it serves. For more information, please contact PHX at 610-983-1811.
McGlinn Cancer Institute at Pottstown Hospital
Pottstown Hospital is a 213-bed facility located at 1600 High Street in Pottstown, PA. It offers a full range of health services, including inpatient, outpatient, medical, surgical, diagnostic and emergency care. The hospital is also fully accredited by The Joint Commission. Pottstown Hospital has been recognized for its quality outcomes and clinical expertise afforded to its surrounding community members.
As a satellite location for the McGlinn Cancer Institute, its cancer program is nationally recognized. It is Heart Failure certified, is designated as a Primary Stroke Center and is Joint Commission certified for hip and knee replacements. The McGlinn Cancer Institute at Pottstown maintains a CoC of the ACS accreditation which speaks to its commitment to the standards this distinction is recognized for.
The Pottstown Cancer Research Office (PTN) conducts Phase II-IV NCI funded cooperative group trials, and is an Affiliate Member of ECOG-ACRIN cooperative group and is a part of NCI’s National Clinical Trials Network. Additionally, PTN conducts NRG and other cooperative group trials sponsored by the NCI. Intra-institutional studies with the likes of Thomas Jefferson are conducted in addition to grant-funded research. This comprehensive cancer center and clinical trials site offers a variety of oncology clinical trial opportunities that meet the needs of their distinct community and are known for their excellent research contributions and their superb patient care they deliver. For more information, please contact PTN at 610-327-7772.